Analysis of the key themes driving M&A activity reveals that immuno-oncology acc...
Analysis of the key themes driving M&A activity reveals that orphan designated d...
Neuralink, however closely watched, is still catching up to its peers in the neu...
In the latest edition of STAT's Health Tech newsletter: Omada tackles obesity dr...
Millions of doses into the rollout of a new polio vaccine, it is apparent that t...
The European Medicines Agency recommended revoking marketing authorization for a...
A host of hurdles threaten to hinder the use of newly developed RSV vaccines for...
“You can harm someone at whatever pace you want, but you're still harming them,”...
Underrepresentation of population subgroups in clinical research is bad for the ...
M&A activity for pharma CMOs reached a peak in 2021, with 2022 seeing a slight d...
Rinvoq is expected to have a rapid uptake in the CD market by healthcare provide...
VANFLYTA was first approved as a monotherapy in the relapsed/refractory setting.
The NDA included data from the Phase III FRESCO-2 and FRESCO trials conducted in...
A few weeks after Covid-19 emergency declaration ended, the FDA has approved Pax...
The immune-oncology market is forecasted to grow to over $150 billion by 2028, b...
The larger facility is expected to help Touchlight supply plasmid DNA to meet th...
